PH receives 3 new Covid-19 clinical trial applications radyonatin.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from radyonatin.com Daily Mail and Mail on Sunday newspapers.
FILE PHOTO
Metro Manila (CNN Philippines, May 16) The country received three new COVID-19 vaccine clinical trial applications, Science and Technology Undersecretary Rowena Guevara said Tuesday.
The vaccine developers that applied to conduct Phase 3 trials were the West China Hospital and Sichuan University, Shenzhen Kangtai Biological Products Co., and Eubiologics Co. Ltd., Guevara said in a briefing.
The undersecretary said evaluation of the applications submitted by the West China Hospital and Sichuan University, as well as Shenzhen Kangtai is underway while Eubiologics is still “completing some requirements.”
Meanwhile, the Department of Science Technology is also waiting the World Health Organization s release of its final protocol and list of COVID-19 shots for its Solidarity vaccine trials in the country. Guevara said WHO is expected to submit the documents “by the end of the month.”
BusinessWorld
May 25, 2021 | 8:18 pm
PHILIPPINE STAR/ MICHAEL VARCAS
THREE more coronavirus vaccine developers applied for clinical trials in the Philippines, the Department of Science and Technology said on Tuesday.
In a press briefing, Science and Technology Undersecretary Rowena Cristina L. Guevara said the task group on vaccine evaluation and selection received clinical trial applications from West China Hospital and Sichuan University, Shenzhen Kangtai Biological Products Co., and Eubiologics Co. Ltd.
“Evaluation of the first two new applications are ongoing, while Eubiologics Co. Ltd. are still completing some requirements,” she told an online briefing.
The applications are for phase III clinical trials, she said.
By JULIA MARI ORNEDO, GMA News
Published May 25, 2021 2:06pm Three more COVID-19 vaccine developers have applied for Phase 3 clinical trials in the Philippines, a Department of Science and Technology (DOST) official said Tuesday. DOST Undersecretary Rowena Guevara said the Task Group on Vaccine Evaluation and Selection received applications from the West China Hospital and Sichuan University, Shenzhen Kangtai Biological Products Co., and Eubiologics Co. Ltd. “Evaluation of the first two new applications are ongoing, while Eubiologics Co. Ltd are still completing some requirements,” she said at a health department forum. Guevara did not disclose the vaccine platform and target subjects of the three manufacturers, saying their applications are still undergoing review.